Publicaciones en colaboración con investigadores/as de Yale School of Medicine (35)

2024

  1. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

  2. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity

    Science immunology, Vol. 9, Núm. 94, pp. eadh2334

2023

  1. Mass cytometry to characterize the immune lung cancer microenvironment

    Methods in Cell Biology, Vol. 174, pp. 31-41

2022

  1. Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 7

  2. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  3. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

    Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715

  2. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8

    Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201

  3. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393

  4. Single-cell characterization of a model of poly I:C-stimulated peripheral blood mononuclear cells in severe asthma

    Respiratory Research, Vol. 22, Núm. 1

  5. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas

    Neuro-Oncology, Vol. 23, Núm. 11, pp. 1922-1935

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

    Nature Medicine, Vol. 26, Núm. 5, pp. 688-692

  3. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

    Nature, Vol. 583, Núm. 7817, pp. 609-614

  4. Overview of Lung Cancer Immunotherapy

    Cancer Journal (United States), Vol. 26, Núm. 6, pp. 473-484

  5. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

    Clinical Cancer Research, Vol. 26, Núm. 16, pp. 4186-4197

2019

  1. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

  2. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus

    Science Translational Medicine, Vol. 11, Núm. 522

  3. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

    Nature Medicine, Vol. 25, Núm. 4, pp. 656-666

  4. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 6, pp. 1046-1060